Phase 2 and 3 studies have also reported higher patient preference and healthcare professional satisfaction with H SC compared with H IV, in both HER2-positive early breast cancer (eBC) and mBC (PrefHer and MetaspHer, respectively) [11–13]. This evidence concerns the gene ERBB2 and breast cancer.